CROSS-BORDER IMPACT VENTURES

Thesis

Cross-Border Impact Ventures (CBIV) is a women-owned and women-led impact venture capital firm founded in 2019, with offices in Toronto, London, and Amsterdam. The firm's primary focus is on investing in early-growth-stage health technology companies that aim to improve health outcomes for women, children, and adolescents globally. CBIV's investment thesis is centered on the belief that addressing the underinvestment in women's and children's health presents a significant opportunity for both social impact and financial returns. They invest in companies commercializing medical devices, diagnostics, therapeutics, and digital health innovations, with a particular emphasis on those utilizing AI and ML. CBIV targets companies addressing health conditions that uniquely or disproportionately affect women and children, including maternal and child care, sexual and reproductive health, and specific diseases. The firm primarily invests in Series A and Series B rounds, with a global geographic scope focusing on North America and Europe, while also seeking opportunities in low- and middle-income countries. For its second fund, CBIV also integrates a climate lens into its investment process. The firm's first fund, Women's and Children's Health Technology Fund I, raised $90.3 million, and its second fund, Women's and Children's Health Technology Fund II, secured $58 million towards a $125 million target.

Related lists

• Series A AI investors
• Series A Healthcare investors
• Series B AI investors